Abstract: An exposure device includes: an optical system member that causes light irradiated from a light emitting element to converge; an optical system support part that supports the optical system member; and a fixing member for fixing the optical system member to the optical system holding part. An elongation of the fixing member is in a range of 40% to 80% inclusive.

Abstract: Novel therapeutic agents for myeloma are provided. A therapeutic agent for multiple myeloma containing a pyrazole compound represented by the formula (1): wherein R1 is C1-C6 alkyl, C1-C6 alkyl substituted with R17, C1-C6 haloalkyl, phenyl, phenyl substituted with a R11's or the like, R2 is a hydrogen atom, C1-C6 alkyl, phenyl or phenyl optionally substituted with e R21's or the like, R3 is a hydrogen atom or the like, X is a single bond or —(CR6R7)n—, each of R4 and R5 is independently C1-C6 alkyl or the like, R6 and R7 are hydrogen atoms or C1-C6 alkyl, R8 is phenyl, phenyl optionally substituted with k R81's or the like, a tautomer of the compound or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

Abstract: An exposure device includes: a substrate on which a plurality of light emitting elements are mounted; an optical system that converges light irradiated from the light emitting elements onto a photosensitive surface; a holding member that holds and fixes the substrate; a support member that supports the optical system and the holding member; a first adhesive member that is provided between the substrate and the holding member; and a second adhesive member that is provided between the holding member and the support member, wherein the first adhesive member has higher elongation and lower hardness than the second adhesive member.

Abstract: Novel therapeutic agents for myeloma are provided. A therapeutic agent for multiple myeloma containing a pyrazole compound represented by the formula (1): wherein R1 is C1-C6 alkyl, C1-C6 alkyl substituted with R17, C1-C6 haloalkyl, phenyl, phenyl substituted with a R11's or the like, R2 is a hydrogen atom, C1-C6 alkyl, phenyl or phenyl optionally substituted with e R21's or the like, R3 is a hydrogen atom or the like, X is a single bond or —(CR6, R7)n—, each of R4 and R5 is independently C1-C6 alkyl or the like, R6 and R7 are hydrogen atoms or C1-C6 alkyl, R8 is phenyl, phenyl optionally substituted with k R81's or the like, a tautomer of the compound or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

Abstract: An exposure device includes: a substrate on which a plurality of light emitting elements are mounted; an optical system that converges light irradiated from the light emitting elements onto a photosensitive surface; a holding member that holds and fixes the substrate; a support member that supports the optical system and the holding member; a first adhesive member that is tprovided between the substrate and the holding member; and a second adhesive member that is provided between the holding member and the support member, wherein the first adhesive member has higher elongation and lower hardness than the second adhesive member.

Abstract: An exposure device includes: an optical system member that causes light irradiated from a light emitting element to converge; an optical system support part that supports the optical system member; and a fixing member for fixing the optical system member to the optical system holding part. An elongation of the fixing member is in a range of 40% to 80% inclusive.